Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01406444 · ClinicalTrials.gov registry record · NA
IGF-1 and Bone Loss in Women With Anorexia Nervosa
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 148
- Enrollment target
NCT01406444: Completed NA study, sponsored by Massachusetts General Hospital.
NCT01406444 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 148 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01406444, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 148 participants
- Enrollment target
Study Summary
Anorexia nervosa is an eating disorder that can cause thinning of the bones (a decrease in bone density). A significant decrease in bone density is called osteopenia or osteoporosis. Sometimes the loss of bone density can be severe enough to cause breaks and fractures of the bones. It is not known what causes the bones to thin in anorexia nervosa. Women who have this condition often have thin or weak bones that are more likely to break. They also have very low levels of a chemical called IGF-1 in their body. This chemical is very important for increasing bone growth in puberty and for maintaining healthy adult bones. The investigators would like to find out if giving rhIGF-1 followed by risedronate or risedronate alone can lead to an increase in bone formation, bone density, and bone strength in women with anorexia nervosa.
Interventions
- DRUG Placebo
- DRUG Risedronate
- DRUG rhIGF-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2011-10 |
| Est. Completion | 2019-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01406444
The ClinicalTrials.gov registry entry for NCT01406444 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01406444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01406444 about?
NCT01406444 is a clinical study titled "IGF-1 and Bone Loss in Women With Anorexia Nervosa". Anorexia nervosa is an eating disorder that can cause thinning of the bones (a decrease in bone density). A significant decrease in bone density is called osteopenia or osteoporosis. Sometimes the loss of bone density can be severe enough to cause breaks and fractures of the bones. It is not known w...
What is the current status of trial NCT01406444?
This trial is currently completed. It is a NA study. The enrollment target is 148 participants. The study started on 2011-10. Estimated completion is 2019-05.
What interventions are being tested in trial NCT01406444?
The interventions under investigation include: Placebo (DRUG), Risedronate (DRUG), rhIGF-1 (DRUG).
Who is sponsoring clinical trial NCT01406444?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.